vs

Side-by-side financial comparison of Allot Ltd. (ALLT) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.

Allot Ltd. is the larger business by last-quarter revenue ($24.1M vs $13.3M, roughly 1.8× OCULAR THERAPEUTIX, INC). Allot Ltd. runs the higher net margin — -7.0% vs -488.0%, a 480.9% gap on every dollar of revenue. On growth, Allot Ltd. posted the faster year-over-year revenue change (8.5% vs -22.4%). Allot Ltd. produced more free cash flow last quarter ($4.0M vs $-57.1M).

Allot Ltd., formerly Allot Communications, is an Israeli high-tech company that develops telecommunications software. The company is headquartered in Hod Hasharon, Israel.

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

ALLT vs OCUL — Head-to-Head

Bigger by revenue
ALLT
ALLT
1.8× larger
ALLT
$24.1M
$13.3M
OCUL
Growing faster (revenue YoY)
ALLT
ALLT
+31.0% gap
ALLT
8.5%
-22.4%
OCUL
Higher net margin
ALLT
ALLT
480.9% more per $
ALLT
-7.0%
-488.0%
OCUL
More free cash flow
ALLT
ALLT
$61.1M more FCF
ALLT
$4.0M
$-57.1M
OCUL

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
ALLT
ALLT
OCUL
OCUL
Revenue
$24.1M
$13.3M
Net Profit
$-1.7M
$-64.7M
Gross Margin
72.1%
88.0%
Operating Margin
-1.7%
-526.5%
Net Margin
-7.0%
-488.0%
Revenue YoY
8.5%
-22.4%
Net Profit YoY
49.6%
-33.6%
EPS (diluted)
$-0.04
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALLT
ALLT
OCUL
OCUL
Q4 25
$13.3M
Q3 25
$14.5M
Q2 25
$24.1M
$13.5M
Q1 25
$23.1M
$10.7M
Q4 24
$17.1M
Q3 24
$15.4M
Q2 24
$22.2M
$16.4M
Q1 24
$14.8M
Net Profit
ALLT
ALLT
OCUL
OCUL
Q4 25
$-64.7M
Q3 25
$-69.4M
Q2 25
$-1.7M
$-67.8M
Q1 25
$-332.0K
$-64.1M
Q4 24
$-48.4M
Q3 24
$-36.5M
Q2 24
$-3.4M
$-43.8M
Q1 24
$-64.8M
Gross Margin
ALLT
ALLT
OCUL
OCUL
Q4 25
88.0%
Q3 25
87.8%
Q2 25
72.1%
85.6%
Q1 25
69.3%
88.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
68.5%
90.8%
Q1 24
91.0%
Operating Margin
ALLT
ALLT
OCUL
OCUL
Q4 25
-526.5%
Q3 25
-472.3%
Q2 25
-1.7%
-502.6%
Q1 25
-3.1%
-597.5%
Q4 24
-296.1%
Q3 24
-298.2%
Q2 24
-15.2%
-265.1%
Q1 24
-214.0%
Net Margin
ALLT
ALLT
OCUL
OCUL
Q4 25
-488.0%
Q3 25
-477.3%
Q2 25
-7.0%
-503.9%
Q1 25
-1.4%
-598.7%
Q4 24
-283.3%
Q3 24
-236.6%
Q2 24
-15.1%
-266.3%
Q1 24
-438.9%
EPS (diluted)
ALLT
ALLT
OCUL
OCUL
Q4 25
$-0.27
Q3 25
$-0.38
Q2 25
$-0.04
$-0.39
Q1 25
$-0.01
$-0.38
Q4 24
$-0.25
Q3 24
$-0.22
Q2 24
$-0.09
$-0.26
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALLT
ALLT
OCUL
OCUL
Cash + ST InvestmentsLiquidity on hand
$60.1M
$737.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$99.7M
$654.3M
Total Assets
$154.1M
$808.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALLT
ALLT
OCUL
OCUL
Q4 25
$737.1M
Q3 25
$344.8M
Q2 25
$60.1M
$391.1M
Q1 25
$10.1M
$349.7M
Q4 24
$392.1M
Q3 24
$427.2M
Q2 24
$15.9M
$459.7M
Q1 24
$482.9M
Stockholders' Equity
ALLT
ALLT
OCUL
OCUL
Q4 25
$654.3M
Q3 25
$258.2M
Q2 25
$99.7M
$305.9M
Q1 25
$50.0M
$265.9M
Q4 24
$315.3M
Q3 24
$352.0M
Q2 24
$46.7M
$377.7M
Q1 24
$408.0M
Total Assets
ALLT
ALLT
OCUL
OCUL
Q4 25
$808.1M
Q3 25
$410.9M
Q2 25
$154.1M
$451.3M
Q1 25
$140.3M
$405.9M
Q4 24
$457.9M
Q3 24
$490.4M
Q2 24
$132.5M
$517.1M
Q1 24
$538.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALLT
ALLT
OCUL
OCUL
Operating Cash FlowLast quarter
$4.4M
$-54.2M
Free Cash FlowOCF − Capex
$4.0M
$-57.1M
FCF MarginFCF / Revenue
16.5%
-430.9%
Capex IntensityCapex / Revenue
1.7%
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-6.0M
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALLT
ALLT
OCUL
OCUL
Q4 25
$-54.2M
Q3 25
$-50.7M
Q2 25
$4.4M
$-55.2M
Q1 25
$1.7M
$-44.7M
Q4 24
$-39.4M
Q3 24
$-36.6M
Q2 24
$1.2M
$-24.8M
Q1 24
$-33.9M
Free Cash Flow
ALLT
ALLT
OCUL
OCUL
Q4 25
$-57.1M
Q3 25
$-56.7M
Q2 25
$4.0M
$-56.5M
Q1 25
$1.4M
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$217.0K
$-25.5M
Q1 24
$-34.1M
FCF Margin
ALLT
ALLT
OCUL
OCUL
Q4 25
-430.9%
Q3 25
-390.0%
Q2 25
16.5%
-419.7%
Q1 25
6.1%
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
1.0%
-155.4%
Q1 24
-231.1%
Capex Intensity
ALLT
ALLT
OCUL
OCUL
Q4 25
21.4%
Q3 25
41.2%
Q2 25
1.7%
9.3%
Q1 25
1.2%
18.1%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.3%
4.5%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons